Effects of calcisorb on fecal bile acids and fatty acids in human volunteers.

A. van Faassen, A.A. Bogaard, M.J. Hazen, P. Geerlings, R.J.J. Hermus, R.A. Janknegt

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)

Abstract

Effects of calcisorb on fecal bile acids and fatty acids in human volunteers.

van Faassen A, van den Bogaard AE, Hazen MJ, Geerlings P, Hermus RJ, Janknegt RA.

Department of Urology, University Hospital Maastricht, The Netherlands.

The intake of calcium (Ca) is negatively associated with colorectal cancer (crc) risk. The aim of this study was to investigate in a double-blind, placebo-controlled trial, the effects of the Ca-binder Calcisorb, which is given to kidney stone patients with hypercalciuria type I, on risk factors for crc risk, bile acids (BA), and long-chain fatty acids (LCFA) in fecal water. Results show that the concentration of BA and LCFA in fecal water did not change, although the urinary excretion of Ca and magnesium (Mg) and the concentration of Ca and magnesium in fecal water decreased. The daily excretion of BA and LCFA acids decreased significantly (p < 0.05) during the Calcisorb period. In conclusion, binding dietary Ca and Mg with Calcisorb from a diet with a relatively low amount of fat does not enhance the solubility of BA and LCFA in fecal water.

Publication Types:
Clinical Trial
Controlled Clinical Trial
Original languageEnglish
Pages (from-to)2319-2325
JournalDigestive Diseases and Sciences
Volume41
DOIs
Publication statusPublished - 1 Jan 1996

Cite this

van Faassen, A., Bogaard, A. A., Hazen, M. J., Geerlings, P., Hermus, R. J. J., & Janknegt, R. A. (1996). Effects of calcisorb on fecal bile acids and fatty acids in human volunteers. Digestive Diseases and Sciences, 41, 2319-2325. https://doi.org/10.1007/BF02100121